Lv7
3530 积分 2021-04-01 加入
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
13天前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
28天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
28天前
已完结
Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
1个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
1个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2个月前
已完结
Biology and regulation of IL-2: from molecular mechanisms to human therapy
2个月前
已完结
Extension Reports in Clinical Trials
2个月前
已完结
皖公网安备34019202002308
